Verseon gets approval for VE-1902 clinical trial
13th Sep 2018 08:06
(Sharecast News) - Technology-based pharmaceutical company Verseon has received ethics committee approval and acknowledgement from the Therapeutic Goods Administration in Australia for the phase I clinical trial of VE-1902, it announced on Thursday.
Read moreVerseon losses widen as VE-1902 trials continue
8th Aug 2018 09:21
(Sharecast News) - Pharmaceutical company Verseon said interim losses widened 15.9% to $10.2m as the US-based firm's operating expenses increased 7.37%.
Read moreVerseon granted two important US patents
4th Jan 2017 12:32
(ShareCast News) - Technology-based pharmaceutical company Verseon announced on Wednesday that the United States Patent and Trademark Office has granted US Patents No. 9,533,967 and 9,533,970, which cover various aspects of multiple families of compounds that were designed by the company for its dru
Read moreVerseon shares rise as firm buys new lab location
20th Aug 2015 15:34
(ShareCast News) - Shares in drug discovery company Verseon Corporation were up after the firm said it bought an $8.7m property for a new lab. At 1537 BST shares in the AIM listed company were up by 2.02% to 227p at 1425 BST. The building, which has about 85,000 square feet of useable space, would
Read more